BridgeMD
New treatment option for Ovarian Neoplasm Epithelial
Official title OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
ClinicalTrials.gov ID: NCT06466382
What this study is testing
What is Carboplatin / Paclitaxel Chemotherapy?
Carboplatin / Paclitaxel Chemotherapy is an investigational medicine, given as an once-weekly, being studied as a potential treatment for ovarian neoplasm epithelial.
Also referred to as Standard of care chemotherapy regime.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV
- No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis
- Envisaged surgical candidate for interval debulking after 2 cycles of treatment
- Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures
- ECOG 0-2
You likely can't join if
- Elevated liver enzymes (double of normal range: ASAT \> 68 U/l; ALAT \> 82 U/l; GGT \> 80 U/l)
- Elevated creatinine (double of normal range: \>120 mmol/l))
- ECOG ≥3
- Pregnant or lactating women
- Any other malignancy within the last 5 years which has an impact on the prognosis of the patient
- Inability to swallow tablets
See the full eligibility criteria
- Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV
- No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis
- Envisaged surgical candidate for interval debulking after 2 cycles of treatment
- Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures
- ECOG 0-2
- Written informed consent according to national legal and regulatory requirements prior to any project specific procedures
- Elevated liver enzymes (double of normal range: ASAT \> 68 U/l; ALAT \> 82 U/l; GGT \> 80 U/l)
- Elevated creatinine (double of normal range: \>120 mmol/l))
- ECOG ≥3
- Pregnant or lactating women
- Any other malignancy within the last 5 years which has an impact on the prognosis of the patient
- Inability to swallow tablets
- Concurrent participation in another clinical trial on the same indication
- Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance
The study team makes the final eligibility decision.
Where it's taking place
- Baden, Canton of Aargau, Switzerland
- Basel, Canton of Basel-City, Switzerland
- Sankt Gallen, Canton of St. Gallen, Switzerland
- Frauenfeld, Thurgau, Switzerland
- Bern, Switzerland
- Fribourg, Switzerland
- Zurich, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Baden, Canton of Aargau, Switzerland; Basel, Canton of Basel-City, Switzerland; Sankt Gallen, Canton of St. Gallen, Switzerland; Frauenfeld, Thurgau, Switzerland; Bern, Switzerland; Fribourg, Switzerland and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.